WHO conditionally recommends GLP-1 drugs for obesity
Posted on: Dec 01, 2025 20:22 IST | Posted by: Cbc
The domain wellness organisation on mon issued its number one guideline on the use of GLP-1 therapies for obesity, conditionally recommending them as part of long-term treatment for the condition, which affects more than one billion people globally, according to the agency.
The guidance comes as demand for the class of drugs known as GLP-1 agonists has surged worldwide, and governments are figuring out how to include the blockbuster therapies in public health systems.
The first conditional recommendation advises the use of GLP-1 drugs by adults, except pregnant women, for long-term obesity treatment, while the second suggests interventions like a healthy diet and physical activity to be offered alongside the medicines.
WHO Director-General Tedros Adhanom Ghebreyesus said the new guidance "recognizes that obesity is a chronic disease that can be treated with comprehensive and lifelong care."
Do drugs like Ozempic kill your desire for more than just food?
He added that although medication alone cannot solve this global health crisis, GLP-1 medication could help millions overcome this condition and reduce its associated harms.
Reuters first reported that the WHO was likely to take this step earlier this year.
The latest move builds on the agency's decision in September to add semaglutide and tirzepatide, active ingredients in Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, to its essential medicines list for managing type 2 diabetes in high-risk groups.
The agency warned on Monday that the economic toll of obesity was rising sharply, with the annual global cost to reach $3 trillion US by 2030.
WHO also stressed that access remains a major barrier. Even with rapid expansion in production, GLP-1 therapies are projected to reach fewer than 10 per cent of those who could benefit, by 2030.
The latest guideline applies to adults with a body mass index of 30 or higher and the recommendations are for three agents — semaglutide, tirzepatide and an older drug from the same class called liraglutide.
WHO said it will work with governments and stakeholders in 2026 to help prioritize access for people at the highest health risk.
Global News Perspectives
In today's interconnected world, staying informed about global events is more important than ever. ZisNews provides news coverage from multiple countries, allowing you to compare how different regions report on the same stories. This unique approach helps you gain a broader and more balanced understanding of international affairs. Whether it's politics, business, technology, or cultural trends, ZisNews ensures that you get a well-rounded perspective rather than a one-sided view. Expand your knowledge and see how global narratives unfold from different angles.
Customizable News Feed
At ZisNews, we understand that not every news story interests everyone. That's why we offer a customizable news feed, allowing you to control what you see. By adding keywords, you can filter out unwanted news, blocking articles that contain specific words in their titles or descriptions. This feature enables you to create a personalized experience where you only receive content that aligns with your interests. Register today to take full advantage of this functionality and enjoy a distraction-free news feed.
Like or Comment on News
Stay engaged with the news by interacting with stories that matter to you. Like or dislike articles based on your opinion, and share your thoughts in the comments section. Join discussions, see what others are saying, and be a part of an informed community that values meaningful conversations.
Download the Android App
For a seamless news experience, download the ZisNews Android app. Get instant notifications based on your selected categories and stay updated on breaking news. The app also allows you to block unwanted news, ensuring that you only receive content that aligns with your preferences. Stay connected anytime, anywhere.
Diverse News Categories
With ZisNews, you can explore a wide range of topics, ensuring that you never miss important developments. From Technology and Science to Sports, Politics, and Entertainment, we bring you the latest updates from the world's most trusted sources. Whether you are interested in groundbreaking scientific discoveries, tech innovations, or major sports events, our platform keeps you updated in real-time. Our carefully curated news selection helps you stay ahead, providing accurate and relevant stories tailored to diverse interests.
No comments yet.